Burosumab-twza for Tumor-Induced Osteomalacia: Suzanne Jan de Beur, MD

In this interview with i3 Health, Suzanne Jan de Beur, MD, discusses the recent approval of burosumab-twza (Crysvita®, Ultragenyx Pharmaceutical, Inc.), for patients with tumor-induced osteomalacia (TIO) whose tumors are unable to be localized or resected. Dr. Jan de Beur, lead investigator of one of the phase 2 clinical trials on which the approval was based, explains the challenges involved in diagnosing and treating TIO and discusses the significance of the approval of burosumab-twza for pati...
Continue reading

Tumor-Induced Osteomalacia: Burosumab-twza Approved

The FDA has approved burosumab-twza (Crysvita®, Ultragenyx Pharmaceutical, Inc.), a fully human monoclonal antibody, for the treatment of patients aged two and older with tumor-induced osteomalacia (TIO) whose tumors are unable to be located or removed. A rare condition, TIO develops when tumors secrete high levels of fibroblast growth factor 23 (FGF23), a peptide hormone–like substance which lowers phosphate levels, thereby weakening and softening the bones. Patients with TIO can experience bon...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.